Immune evasion in cancer

Mechanistic basis and therapeutic strategies

Dass S. Vinay, Elizabeth P. Ryan, Graham Pawelec, Wamidh H. Talib, John Stagg, Eyad Elkord, Terry Lichtor, William K. Decker, Richard L. Whelan, H. M C Shantha Kumara, Emanuela Signori, Kanya Honoki, Alexandros G. Georgakilas, Amr Amin, William G. Helferich, Chandra S. Boosani, Gunjan Guha, Maria Rosa Ciriolo, Sophie Chen, Sulma I. Mohammed & 12 others Asfar S. Azmi, W. Nicol Keith, Alan Bilsland, Dipita Bhakta, Dorota Halicka, Hiromasa Fujii, Katia Aquilano, S. Salman Ashraf, Somaira Nowsheen, Xujuan Yang, Beom K. Choi, Byoung S. Kwon

Research output: Contribution to journalReview article

276 Citations (Scopus)

Abstract

Cancer immune evasion is a major stumbling block in designing effective anticancer therapeutic strategies. Although considerable progress has been made in understanding how cancers evade destructive immunity, measures to counteract tumor escape have not kept pace. There are a number of factors that contribute to tumor persistence despite having a normal host immune system. Immune editing is one of the key aspects why tumors evade surveillance causing the tumors to lie dormant in patients for years through "equilibrium" and "senescence" before re-emerging. In addition, tumors exploit several immunological processes such as targeting the regulatory T cell function or their secretions, antigen presentation, modifying the production of immune suppressive mediators, tolerance and immune deviation. Besides these, tumor heterogeneity and metastasis also play a critical role in tumor growth. A number of potential targets like promoting Th1, NK cell, γδ T cell responses, inhibiting Treg functionality, induction of IL-12, use of drugs including phytochemicals have been designed to counter tumor progression with much success. Some natural agents and phytochemicals merit further study. For example, use of certain key polysaccharide components from mushrooms and plants have shown to possess therapeutic impact on tumor-imposed genetic instability, anti-growth signaling, replicative immortality, dysregulated metabolism etc. In this review, we will discuss the advances made toward understanding the basis of cancer immune evasion and summarize the efficacy of various therapeutic measures and targets that have been developed or are being investigated to enhance tumor rejection.

Original languageEnglish
Pages (from-to)S185-S198
JournalSeminars in Cancer Biology
Volume35
DOIs
Publication statusPublished - 1 Dec 2015
Externally publishedYes

Fingerprint

Immune Evasion
Neoplasms
Therapeutics
Phytochemicals
Tumor Escape
Plant Structures
Immune Tolerance
Th1 Cells
Agaricales
Antigen Presentation
Regulatory T-Lymphocytes
Interleukin-12
Growth
Natural Killer Cells
Polysaccharides
Immune System
Immunity

Keywords

  • Cancer
  • Immune evasion
  • T cells
  • Therapy

ASJC Scopus subject areas

  • Cancer Research

Cite this

Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., ... Kwon, B. S. (2015). Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Seminars in Cancer Biology, 35, S185-S198. https://doi.org/10.1016/j.semcancer.2015.03.004

Immune evasion in cancer : Mechanistic basis and therapeutic strategies. / Vinay, Dass S.; Ryan, Elizabeth P.; Pawelec, Graham; Talib, Wamidh H.; Stagg, John; Elkord, Eyad; Lichtor, Terry; Decker, William K.; Whelan, Richard L.; Kumara, H. M C Shantha; Signori, Emanuela; Honoki, Kanya; Georgakilas, Alexandros G.; Amin, Amr; Helferich, William G.; Boosani, Chandra S.; Guha, Gunjan; Ciriolo, Maria Rosa; Chen, Sophie; Mohammed, Sulma I.; Azmi, Asfar S.; Keith, W. Nicol; Bilsland, Alan; Bhakta, Dipita; Halicka, Dorota; Fujii, Hiromasa; Aquilano, Katia; Ashraf, S. Salman; Nowsheen, Somaira; Yang, Xujuan; Choi, Beom K.; Kwon, Byoung S.

In: Seminars in Cancer Biology, Vol. 35, 01.12.2015, p. S185-S198.

Research output: Contribution to journalReview article

Vinay, DS, Ryan, EP, Pawelec, G, Talib, WH, Stagg, J, Elkord, E, Lichtor, T, Decker, WK, Whelan, RL, Kumara, HMCS, Signori, E, Honoki, K, Georgakilas, AG, Amin, A, Helferich, WG, Boosani, CS, Guha, G, Ciriolo, MR, Chen, S, Mohammed, SI, Azmi, AS, Keith, WN, Bilsland, A, Bhakta, D, Halicka, D, Fujii, H, Aquilano, K, Ashraf, SS, Nowsheen, S, Yang, X, Choi, BK & Kwon, BS 2015, 'Immune evasion in cancer: Mechanistic basis and therapeutic strategies', Seminars in Cancer Biology, vol. 35, pp. S185-S198. https://doi.org/10.1016/j.semcancer.2015.03.004
Vinay, Dass S. ; Ryan, Elizabeth P. ; Pawelec, Graham ; Talib, Wamidh H. ; Stagg, John ; Elkord, Eyad ; Lichtor, Terry ; Decker, William K. ; Whelan, Richard L. ; Kumara, H. M C Shantha ; Signori, Emanuela ; Honoki, Kanya ; Georgakilas, Alexandros G. ; Amin, Amr ; Helferich, William G. ; Boosani, Chandra S. ; Guha, Gunjan ; Ciriolo, Maria Rosa ; Chen, Sophie ; Mohammed, Sulma I. ; Azmi, Asfar S. ; Keith, W. Nicol ; Bilsland, Alan ; Bhakta, Dipita ; Halicka, Dorota ; Fujii, Hiromasa ; Aquilano, Katia ; Ashraf, S. Salman ; Nowsheen, Somaira ; Yang, Xujuan ; Choi, Beom K. ; Kwon, Byoung S. / Immune evasion in cancer : Mechanistic basis and therapeutic strategies. In: Seminars in Cancer Biology. 2015 ; Vol. 35. pp. S185-S198.
@article{847d325de13943f282b2618f7e1275ec,
title = "Immune evasion in cancer: Mechanistic basis and therapeutic strategies",
abstract = "Cancer immune evasion is a major stumbling block in designing effective anticancer therapeutic strategies. Although considerable progress has been made in understanding how cancers evade destructive immunity, measures to counteract tumor escape have not kept pace. There are a number of factors that contribute to tumor persistence despite having a normal host immune system. Immune editing is one of the key aspects why tumors evade surveillance causing the tumors to lie dormant in patients for years through {"}equilibrium{"} and {"}senescence{"} before re-emerging. In addition, tumors exploit several immunological processes such as targeting the regulatory T cell function or their secretions, antigen presentation, modifying the production of immune suppressive mediators, tolerance and immune deviation. Besides these, tumor heterogeneity and metastasis also play a critical role in tumor growth. A number of potential targets like promoting Th1, NK cell, γδ T cell responses, inhibiting Treg functionality, induction of IL-12, use of drugs including phytochemicals have been designed to counter tumor progression with much success. Some natural agents and phytochemicals merit further study. For example, use of certain key polysaccharide components from mushrooms and plants have shown to possess therapeutic impact on tumor-imposed genetic instability, anti-growth signaling, replicative immortality, dysregulated metabolism etc. In this review, we will discuss the advances made toward understanding the basis of cancer immune evasion and summarize the efficacy of various therapeutic measures and targets that have been developed or are being investigated to enhance tumor rejection.",
keywords = "Cancer, Immune evasion, T cells, Therapy",
author = "Vinay, {Dass S.} and Ryan, {Elizabeth P.} and Graham Pawelec and Talib, {Wamidh H.} and John Stagg and Eyad Elkord and Terry Lichtor and Decker, {William K.} and Whelan, {Richard L.} and Kumara, {H. M C Shantha} and Emanuela Signori and Kanya Honoki and Georgakilas, {Alexandros G.} and Amr Amin and Helferich, {William G.} and Boosani, {Chandra S.} and Gunjan Guha and Ciriolo, {Maria Rosa} and Sophie Chen and Mohammed, {Sulma I.} and Azmi, {Asfar S.} and Keith, {W. Nicol} and Alan Bilsland and Dipita Bhakta and Dorota Halicka and Hiromasa Fujii and Katia Aquilano and Ashraf, {S. Salman} and Somaira Nowsheen and Xujuan Yang and Choi, {Beom K.} and Kwon, {Byoung S.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.semcancer.2015.03.004",
language = "English",
volume = "35",
pages = "S185--S198",
journal = "Seminars in Cancer Biology",
issn = "1044-579X",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Immune evasion in cancer

T2 - Mechanistic basis and therapeutic strategies

AU - Vinay, Dass S.

AU - Ryan, Elizabeth P.

AU - Pawelec, Graham

AU - Talib, Wamidh H.

AU - Stagg, John

AU - Elkord, Eyad

AU - Lichtor, Terry

AU - Decker, William K.

AU - Whelan, Richard L.

AU - Kumara, H. M C Shantha

AU - Signori, Emanuela

AU - Honoki, Kanya

AU - Georgakilas, Alexandros G.

AU - Amin, Amr

AU - Helferich, William G.

AU - Boosani, Chandra S.

AU - Guha, Gunjan

AU - Ciriolo, Maria Rosa

AU - Chen, Sophie

AU - Mohammed, Sulma I.

AU - Azmi, Asfar S.

AU - Keith, W. Nicol

AU - Bilsland, Alan

AU - Bhakta, Dipita

AU - Halicka, Dorota

AU - Fujii, Hiromasa

AU - Aquilano, Katia

AU - Ashraf, S. Salman

AU - Nowsheen, Somaira

AU - Yang, Xujuan

AU - Choi, Beom K.

AU - Kwon, Byoung S.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Cancer immune evasion is a major stumbling block in designing effective anticancer therapeutic strategies. Although considerable progress has been made in understanding how cancers evade destructive immunity, measures to counteract tumor escape have not kept pace. There are a number of factors that contribute to tumor persistence despite having a normal host immune system. Immune editing is one of the key aspects why tumors evade surveillance causing the tumors to lie dormant in patients for years through "equilibrium" and "senescence" before re-emerging. In addition, tumors exploit several immunological processes such as targeting the regulatory T cell function or their secretions, antigen presentation, modifying the production of immune suppressive mediators, tolerance and immune deviation. Besides these, tumor heterogeneity and metastasis also play a critical role in tumor growth. A number of potential targets like promoting Th1, NK cell, γδ T cell responses, inhibiting Treg functionality, induction of IL-12, use of drugs including phytochemicals have been designed to counter tumor progression with much success. Some natural agents and phytochemicals merit further study. For example, use of certain key polysaccharide components from mushrooms and plants have shown to possess therapeutic impact on tumor-imposed genetic instability, anti-growth signaling, replicative immortality, dysregulated metabolism etc. In this review, we will discuss the advances made toward understanding the basis of cancer immune evasion and summarize the efficacy of various therapeutic measures and targets that have been developed or are being investigated to enhance tumor rejection.

AB - Cancer immune evasion is a major stumbling block in designing effective anticancer therapeutic strategies. Although considerable progress has been made in understanding how cancers evade destructive immunity, measures to counteract tumor escape have not kept pace. There are a number of factors that contribute to tumor persistence despite having a normal host immune system. Immune editing is one of the key aspects why tumors evade surveillance causing the tumors to lie dormant in patients for years through "equilibrium" and "senescence" before re-emerging. In addition, tumors exploit several immunological processes such as targeting the regulatory T cell function or their secretions, antigen presentation, modifying the production of immune suppressive mediators, tolerance and immune deviation. Besides these, tumor heterogeneity and metastasis also play a critical role in tumor growth. A number of potential targets like promoting Th1, NK cell, γδ T cell responses, inhibiting Treg functionality, induction of IL-12, use of drugs including phytochemicals have been designed to counter tumor progression with much success. Some natural agents and phytochemicals merit further study. For example, use of certain key polysaccharide components from mushrooms and plants have shown to possess therapeutic impact on tumor-imposed genetic instability, anti-growth signaling, replicative immortality, dysregulated metabolism etc. In this review, we will discuss the advances made toward understanding the basis of cancer immune evasion and summarize the efficacy of various therapeutic measures and targets that have been developed or are being investigated to enhance tumor rejection.

KW - Cancer

KW - Immune evasion

KW - T cells

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84926160709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926160709&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2015.03.004

DO - 10.1016/j.semcancer.2015.03.004

M3 - Review article

VL - 35

SP - S185-S198

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

SN - 1044-579X

ER -